133 related articles for article (PubMed ID: 21510297)
1. Switching to sirolimus monotherapy for de novo tumors after liver transplantation. A preliminary experience.
Jiménez-Romero C; Manrique A; Marqués E; Calvo J; Sesma AG; Cambra F; Abradelo M; Sterup RM; Olivares S; Justo I; Colina F; Moreno E
Hepatogastroenterology; 2011; 58(105):115-21. PubMed ID: 21510297
[TBL] [Abstract][Full Text] [Related]
2. Kidney transplantation with sirolimus and mycophenolate mofetil-based immunosuppression: 5-year results of a randomized prospective trial compared to calcineurin inhibitor drugs.
Flechner SM; Goldfarb D; Solez K; Modlin CS; Mastroianni B; Savas K; Babineau D; Kurian S; Salomon D; Novick AC; Cook DJ
Transplantation; 2007 Apr; 83(7):883-92. PubMed ID: 17460558
[TBL] [Abstract][Full Text] [Related]
3. Mycophenolate and sirolimus as calcineurin inhibitor-free immunosuppression improves renal function better than calcineurin inhibitor-reduction in late cardiac transplant recipients with chronic renal failure.
Groetzner J; Kaczmarek I; Schulz U; Stegemann E; Kaiser K; Wittwer T; Schirmer J; Voss M; Strauch J; Wahlers T; Sohn HY; Wagner F; Tenderich G; Stempfle HU; Mueller-Ehmsen J; Schmid C; Vogeser M; Koch KC; Reichenspurner H; Daebritz S; Meiser B; Reichart B;
Transplantation; 2009 Mar; 87(5):726-33. PubMed ID: 19295318
[TBL] [Abstract][Full Text] [Related]
4. Calcineurin inhibitor-sparing regimens in solid organ transplantation: focus on improving renal function and nephrotoxicity.
Flechner SM; Kobashigawa J; Klintmalm G
Clin Transplant; 2008; 22(1):1-15. PubMed ID: 18217899
[TBL] [Abstract][Full Text] [Related]
5. De novo sirolimus-based regimen in Thai renal transplant recipients.
Townamchai N; Avihingsanon Y; Praditpornsilpa K; Tungsanga K; Eiam-Ong S
Transplant Proc; 2008 Sep; 40(7):2206-8. PubMed ID: 18790193
[TBL] [Abstract][Full Text] [Related]
6. A retrospective 15-year review: survival advantage after switching to sirolimus in hepatitis C virus infected liver graft recipients.
Shah M; Shankar A; Gee I; Nash K; Hoare M; Gibbs P; Davies S; Alexander GJ
Aliment Pharmacol Ther; 2015 Feb; 41(4):379-92. PubMed ID: 25496225
[TBL] [Abstract][Full Text] [Related]
7. Long-term results in renal transplant patients with allograft dysfunction after switching from calcineurin inhibitors to sirolimus.
Bumbea V; Kamar N; Ribes D; Esposito L; Modesto A; Guitard J; Nasou G; Durand D; Rostaing L
Nephrol Dial Transplant; 2005 Nov; 20(11):2517-23. PubMed ID: 15985508
[TBL] [Abstract][Full Text] [Related]
8. De-novo calcineurin-inhibitor-free immunosuppression with sirolimus and mycophenolate mofetil after heart transplantation: 5-year results.
Meiser B; Buchholz S; Kaczmarek I
Curr Opin Organ Transplant; 2011 Oct; 16(5):522-8. PubMed ID: 21836511
[TBL] [Abstract][Full Text] [Related]
9. Experience with the use of sirolimus in liver transplantation--use in patients for whom calcineurin inhibitors are contraindicated.
Chang GJ; Mahanty HD; Quan D; Freise CE; Ascher NL; Roberts JP; Stock PG; Hirose R
Liver Transpl; 2000 Nov; 6(6):734-40. PubMed ID: 11084060
[TBL] [Abstract][Full Text] [Related]
10. mTOR inhibitor monotherapy. A good treatment choice in renal transplantation?
Franco-Esteve A; Tordera D; de la Sen ML; Jiménez L; Mas P; Muñoz C; Olivares J
Nefrologia; 2012; 32(5):631-8. PubMed ID: 23013949
[TBL] [Abstract][Full Text] [Related]
11. Sirolimus and mycophenolate mofetil after liver transplantation.
Kniepeiss D; Iberer F; Grasser B; Schaffellner S; Tscheliessnigg KH
Transpl Int; 2003 Jul; 16(7):504-9. PubMed ID: 12687325
[TBL] [Abstract][Full Text] [Related]
12. Mycophenolate mofetil monotherapy in patients who underwent liver transplantation for hepatitis C cirrhosis.
Manrique A; Jiménez C; Ortega P; Abradelo M; Gimeno A; Calvo J; Cambra F; -Sterup RL; Morales JM; Moreno E
Transplant Proc; 2008 Nov; 40(9):2962-4. PubMed ID: 19010160
[TBL] [Abstract][Full Text] [Related]
13. Conversion from Calcineurin Inhibitor-Based Immunosuppression to Mycophenolate Mofetil in Monotherapy Reduces Risk of De Novo Malignancies After Liver Transplantation.
Aguiar D; Martínez-Urbistondo D; D'Avola D; Iñarrairaegui M; Pardo F; Rotellar F; Sangro B; Quiroga J; Herrero JI
Ann Transplant; 2017 Mar; 22():141-147. PubMed ID: 28302995
[TBL] [Abstract][Full Text] [Related]
14. Sirolimus experience in heart transplantation.
Aranda-Dios A; Lage E; Sobrino JM; Mogollón MV; Guisado A; Cabezón S; Hinojosa R; Hernández A; Ordóñez A
Transplant Proc; 2006 Oct; 38(8):2547-9. PubMed ID: 17097997
[TBL] [Abstract][Full Text] [Related]
15. Mycophenolate mofetil monotherapy in liver transplantation.
Pierini A; Mirabella S; Brunati A; Ricchiuti A; Franchello A; Salizzoni M
Transplant Proc; 2005; 37(6):2614-5. PubMed ID: 16182763
[TBL] [Abstract][Full Text] [Related]
16. Switch from calcineurin inhibitors to sirolimus-induced renal recovery in heart transplant recipients in the midterm follow-up.
Bestetti R; Theodoropoulos TA; Burdmann EA; Filho MA; Cordeiro JA; Villafanha D
Transplantation; 2006 Mar; 81(5):692-6. PubMed ID: 16534470
[TBL] [Abstract][Full Text] [Related]
17. Long-term follow-up of 100 high-risk renal transplant recipients converted from calcineurin inhibitors to sirolimus: a single center experience.
Halim MA; Al-Otaibi T; Johny KV; Hamid MH; Tawab KA; Balaha MA; Abraham M; Said T; Nair MP; Al-Waheeb S; Al-Muzairai I; Nampoory MR
Transplant Proc; 2009 Jun; 41(5):1666-70. PubMed ID: 19545704
[TBL] [Abstract][Full Text] [Related]
18. Conversion to everolimus dramatically improves the prognosis of de novo malignancies after liver transplantation for alcoholic liver disease.
Thimonier E; Guillaud O; Walter T; Decullier E; Vallin M; Boillot O; Dumortier J
Clin Transplant; 2014 Dec; 28(12):1339-48. PubMed ID: 25081431
[TBL] [Abstract][Full Text] [Related]
19. Long-term mycophenolate mofetil monotherapy in combination with calcineurin inhibitors for chronic renal dysfunction after liver transplantation.
Raimondo ML; Dagher L; Papatheodoridis GV; Rolando N; Patch DW; Davidson BR; Rolles K; Burroughs AK
Transplantation; 2003 Jan; 75(2):186-90. PubMed ID: 12548120
[TBL] [Abstract][Full Text] [Related]
20. Renal function, efficacy, and safety of sirolimus and mycophenolate mofetil after short-term calcineurin inhibitor-based quadruple therapy in de novo renal transplant patients: one-year analysis of a randomized multicenter trial.
Guba M; Pratschke J; Hugo C; Krämer BK; Nohr-Westphal C; Brockmann J; Andrassy J; Reinke P; Pressmar K; Hakenberg O; Fischereder M; Pascher A; Illner WD; Banas B; Jauch KW;
Transplantation; 2010 Jul; 90(2):175-83. PubMed ID: 20463641
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
